The BioCentury 100 Index is now up nearly 500%, the longest bull run since the index commenced in the early 1990s (S&P 500 is up 200% over same period). Funding, excluding partnership monies, was a robust $22.7 billion in 2Q, with public offerings 50% higher and debt financings ($7.6 billion) 36% higher than in 2Q14. Private biotech saw a 10% increase in money raised to $3.2 billion, led by a whopping $217-million series A from neurology startup Denali Therapeutics (San Francisco).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yang, W. 2Q15—Running of the biotech bulls. Nat Biotechnol 33, 794 (2015). https://doi.org/10.1038/nbt.3311
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3311
